WBC
RARE icon

Westpac Banking Corp’s Ultragenyx Pharmaceutical RARE Stock Holding History

Westpac Banking Corp’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-32,331
Closed -$1.34M – 783
2022
Q3 		$1.34M Sell
32,331
-22,849
-41% -$1.17M 0.02% 570
2022
Q2 		$3.29M Buy
55,180
+5,800
+12% +$357K 0.04% 442
2022
Q1 		$3.59M Sell
49,380
-1,400
-3% -$97.4K 0.04% 443
2021
Q4 		$4.27M Sell
50,780
-2,300
-4% -$187K 0.04% 429
2021
Q3 		$4.79M Buy
53,080
+4,598
+9% +$416K 0.05% 426
2021
Q2 		$4.62M Sell
48,482
-2,089
-4% -$218K 0.05% 452
2021
Q1 		$5.76M Buy
50,571
+7,100
+16% +$967K 0.06% 376
2020
Q4 		$6.02M Buy
43,471
+4,484
+12% +$532K 0.07% 365
2020
Q3 		$3.2M Buy
38,987
+3,900
+11% +$323K 0.04% 427
2020
Q2 		$2.74M Buy
+35,087
New +$2.32M 0.04% 443

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Westpac Banking Corp's RARE Position: Q4 2022 in Review

Westpac Banking Corp sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 32,331 shares — an estimated $1.34M sold.

Westpac Banking Corp first reported a position in RARE in Q2 2020 and held it in 10 quarters. The position peaked at $6.02M in Q4 2020. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Westpac Banking Corp reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Westpac Banking Corp sold 32,331 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $1.34M.
  • Westpac Banking Corp first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 10 quarters.
  • Westpac Banking Corp's Ultragenyx Pharmaceutical position peaked at $6.02M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Westpac Banking Corp's 13F filing for Q4 2022, filed 6 Feb 2023.